Desmoteplase misses endpoint in stroke

Desmoteplase, one of the few new therapies under development for patients suffering from stroke, has failed to show efficacy in the first of two Phase 3 clinical trials. The developer, H. Lundbeck A/S, said it will seek advice on the way forward.